Bloomage Biotech Secures Patent for Scaled Recombinant PDRN Production, Ushering in a Universal Access Era

A single bacterial strain could unlock billions in value for the global regenerative medicine market. Bloomage Biotech Co., Ltd., the world's largest hyaluronic acid supplier, just secured patent rights for a breakthrough method of producing PDRN—a compound increasingly sought after in anti-aging treatments and wound healing—from Halomonas bacteria.

On July 24, 2026, China's National Intellectual Property Administration granted the patent (authorization number CN121203909B) for what the company calls "Halomonas and its Application in Preparing PDRN and Related Products." The patent, filed November 25, 2025, describes a closed-loop fermentation process that Bloomage says is simpler, safer, and more scalable than existing methods.

The PDRN Race Heats Up

PDRN, or polydeoxyribonucleotide, has become a darling of the aesthetics and regenerative medicine industries. The compound, traditionally extracted from salmon sperm, is used in everything from injectable skin treatments to advanced wound care products. But salmon-based production is expensive and supply-constrained.

Bloomage now claims 21 patents covering PDRN—from raw material preparation to end-user applications—making it the company with the most complete PDRN patent portfolio in China. The company has built three parallel production routes: salmon extraction, microbial fermentation, and synthetic biology.

Its pharmaceutical-grade PDRN factory in Weihai, built to meet EU, U.S., and Chinese regulatory standards, is expected to begin production in the third quarter of 2026 with an annual capacity of approximately 2 metric tons.

From Hyaluronic Acid Dominance to Vertical Integration

Bloomage (688363.SH) already dominates the global hyaluronic acid market. Founded in 2000, the company listed in Hong Kong in 2008, went private in November 2017, and returned to public markets on Shanghai's STAR Market in November 2019.

The company has expanded into four business segments: bioactive raw materials, medical terminal products, dermatological science transformation, and nutritional science transformation. Its product portfolio includes more than 200 specifications of hyaluronic acid—medical, cosmetic, and food grade—alongside other bioactive compounds.

Building a Medical Aesthetics Empire

Bloomage's first hyaluronic acid dermal filler, approved in 2012, was China's first domestically produced product of its kind. Since 2021, the company has restructured its medical aesthetics business under the "Runzhi" brand, positioning it as a "facial rejuvenation expert."

In April 2025, the company received approval for a hyaluronic acid solution containing lidocaine for facial injection. A month later, it secured approval for a compound hyaluronic acid solution with multiple amino acids. Both products target superficial dermal injection for temporary improvement of skin dryness and dullness.

The company has also moved aggressively into collagen. In April 2022, Bloomage acquired a 51% stake in Yierkang Bio for 233 million yuan, entering the animal-source collagen market. By August 2022, the company had declared collagen its second strategic bioactive ingredient after hyaluronic acid.

In December 2025, Bloomage's injection-grade recombinant type III humanized collagen completed medical device master document filing. In January 2026, its cross-linked hyaluronic acid sodium powder followed suit.

Consumer Brands and Strategic Bets

Beyond medical aesthetics, Bloomage has built a portfolio of consumer skincare brands targeting different concerns—from anti-aging to sensitive skin care. In functional foods, it has launched hyaluronic acid drinking water, snacks, and beverages marketed for sleep and beauty benefits.

The company has also pursued strategic investments. In September 2025, Bloomage invested 138 million Hong Kong dollars to acquire a 9.44% stake in Sirnaomics, aiming to leverage the latter's RNAi technology for targeted fat-reduction projects in Greater China. In December 2024, it completed a Series B investment in Nanjing Niubang Bio through its Huaxi Yuanyou Fund.

In July 2025, Bloomage established its first non-animal source heparin full industry chain platform in Shenzhen. That same month, it signed an agreement to build a health food headquarters project in Hangzhou with total investment exceeding 1 billion yuan.

The Universal Access Question

Bloomage frames its latest PDRN patent as the opening of a "universal access era" for the compound. With pharmaceutical-grade production capacity coming online in 2026 and a patent portfolio spanning the entire value chain, the company is positioning itself to supply the PDRN boom sweeping through regenerative medicine and aesthetics.

Whether microbial fermentation can truly democratize access to a compound traditionally dependent on salmon extraction remains to be seen. But Bloomage's bet is clear: the future of PDRN runs through bacteria, not fish.